Why the study?
Does oral enteric-coated aspirin achieve different concentrations in portal and systemic blood and affect platelet aggregation and thromboxane/prostacyclin production in pigs?
Does oral enteric-coated aspirin achieve different concentrations in portal and systemic blood and affect platelet aggregation and thromboxane/prostacyclin production in pigs?
Oral enteric-coated aspirin achieves different concentrations in the portal and systemic circulations in pigs, effectively inhibiting platelet aggregation and thromboxane production.
No takes yet. Share an insight, caveat, or question.
Aspirin effects in this porcine model are hypothesis-generating; leaves open translation to human enteric-coated dosing and practice.
Bochner et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: